Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

GT Biopharma Q3 2026 Results: Net Loss of $3.53M

GT Biopharma reported a net loss of $10.88 million for the nine months ended September 30, 2026, compared to a loss of $22.65 million in the prior year period. The company transitioned to a fully remote model as of July 2024 and maintained a cash balance of $9.92 million as of the reporting date.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-3.58.3
EPS (diluted, $ a share)$-1.98$25.99

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: GTBP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

GT Biopharma, Inc.: key numbers

Share price
$3.18Close, Nov 17
Market cap
$6.8M
Shares outstanding
2.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from GT Biopharma, Inc.

All →
8:31 AM ET 8-K
Capital Raise

GT Biopharma Capital Raise

GT Biopharma shareholders approved a significant increase in authorized common shares from 25 million to 250 million and authorized the issuance of more than 19.99% of outstanding stock. These approvals facilitate the conversion of Series M Preferred Stock and the exercise of warrants related to a Securities Purchase Agreement dated September 14, 2026. The vote ensures compliance with Nasdaq Rule 5635 regarding the potential dilution from these previously announced financing transactions.

4:11 PM ET 8-K
Capital Raise

GT Biopharma Capital Raise of $7.75M

GT Biopharma amended its securities purchase agreement to increase a private placement of Series M 10% Convertible Preferred Stock and warrants, raising the aggregate purchase price to $7.75 million. The deal includes 'Greenshoe Rights' allowing purchasers to potentially acquire additional preferred stock with an aggregate stated value of up to approximately $34.7 million. The company has committed to filing a registration statement for the resale of the underlying common stock within 30 days of closing.

Value
$7.75M
Counterparty
New Purchaser
8:58 AM ET 8-K
Capital Raise

GT Biopharma Capital Raise of $7.45M

GT Biopharma entered into a securities purchase agreement for a private placement of up to 8,277.778 shares of Series M 10% Convertible Preferred Stock and associated warrants for an initial purchase price of $7.45 million. The agreement includes 'Greenshoe Rights' allowing purchasers to acquire additional preferred stock with a stated value of up to $33.33 million for an additional $30 million. The preferred stock is convertible into common stock at an initial conversion price of $6.10 per share.

Value
$7.45M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.